Saniona (SANION) investor relations material

Financial overview and funding

• Market cap currently around SEK 2.2 billion, with share price volatility linked to geopolitical events.

• Strong cash position of SEK 581 million at year-end, with over SEK 800 million available including expected milestone payments and potential sale-leaseback of headquarters.

• Additional SEK 170 million expected from partner deals with Jazz and Acadia in 2026.

• No immediate need for new funding; options for future capital include partnerships, milestone payments, or institutional investment.

Strategic partnerships and deal flow

• Major deals with Jazz and Acadia provide upfront and milestone payments, validating technology and increasing industry visibility.

• Jazz deal: $42.5 million upfront, up to $1 billion total value, phase I start expected this year.

• Acadia deal: $28 million upfront, up to $585 million total value, phase II start expected this year.

• Partnerships with AstronauTx, Boehringer Ingelheim, Cephagenix, and Medix progressing as planned.

Pipeline and clinical development

• Three internal programs: SAN2668 and SAN2219 (epilepsy), SAN2465 (depression), all advancing toward phase I trials by end of year or early 2027.

• Phase I readouts for all three programs expected in the second half of 2027.

• Programs target high unmet needs: drug-resistant epilepsy and fast-acting depression treatments.

• Internal pipeline supported by legacy assets and expertise from NeuroSearch.